Pertuzumab Plus Trastuzumab Shows Meaningful Clinical Activity in Biliary Tract Cancer with ERBB2/3 Alterations

Study at-a-Glance

  • Focus: The study explores the efficacy and safety of the combination therapy of pertuzumab plus trastuzumab in patients with advanced biliary tract cancer (BTC) harboring ERBB2/3 alterations. BTC includes gallbladder cancer, cholangiocarcinoma, and ampullary adenocarcinoma.
  • Population: 29 patients with advanced BTC were included, with a median age of 66 years (range: 34-83). 66% were female, and 52% identified as White, 21% as Black or African American, and 10% as Asian/Asian American.
  • Main Takeaway: The study found that pertuzumab plus trastuzumab met the prespecified criteria to declare a signal of activity in patients with advanced BTC and ERBB2/3 alterations, providing an objective response rate (ORR) of 32% and a disease control rate (DCR) of 40%.
  • Significance: This combination therapy demonstrates notable clinical activity for heavily pretreated patients with BTC, showing potential in managing disease progression in those with ERBB2/3 amplification, overexpression, or mutation.
Login Or Register To Read Full Story